Teva : New products support return to growth
2023 has been a transition year for Teva with the appointment of a new CEO at the beginning of the year and the launch of the “Pivot To Growth” strategy. The group returned to positive revenue growth last year but profitability was hit on an underlying basis by commercial and R&D efforts. Teva should start to bear fruits from its growth initiatives this year with underlying growth adjusted for the upfront payment from Sanofi in 2023. Austedo and Ajovy revenues are increasing at d...Teva Pharmaceutical Industries is engaged in the development, manufacturing, marketing and distribution of generic, specialty, and other pharmaceutical products. The Generic Medicines segment offers a range of basic chemical entities, as well as specialized product families such as sterile products, hormones, narcotics, high-potency drugs and cytotoxic substances, in both parenteral and solid dosage forms. Co.'s specialty medicines business is focused on delivering innovative solutions to patients and providers via medicines, devices and services, includes Co.'s core therapeutic areas of the central nervous system and respiratory medicines.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.